BACKGROUND: Oral contraceptive formulations have changed over time, making it relevant to assess the effect of more recent formulations on breast cancer risk. In addition, some studies have found stronger positive associations of oral contraceptive use with estrogen receptor-negative (ER(-)) than with ER-positive (ER(+)) breast cancer. We carried out the first assessment of the effect of oral contraceptive use on the incidence of breast cancer classified by receptor status among African American women, a group disproportionately affected by ER(-) cancer. METHODS: We followed 53,848 Black Women's Health Study participants from 1995 to 2007 through biennial health questionnaires, in which participants reported information about incident breast cancer, oral contraceptive use, and breast cancer risk factors. Pathology information was obtained on receptor status for 789 incident cases. Incidence rate ratios (IRR) with 95% confidence intervals (95% CI) were derived from Cox regression models with control for confounding factors. RESULTS: Ever use of oral contraceptives was more strongly associated with ER(-)PR(-) breast cancer (279 cases; IRR, 1.65; 95% CI, 1.19-2.30) than with ER(+)PR(+) cancer (386 cases; IRR, 1.11; 95% CI, 0.86-1.42). The risk of ER(-)PR(-) breast cancer increased with increasing duration of use among recent users. CONCLUSIONS: These results indicate that the oral contraceptive formulations used in recent decades increase breast cancer risk in African American women, with a greater effect for ER(-) than ER(+) cancer. IMPACT: Mechanisms to explain the adverse influence of oral contraceptive use on ER(-) breast cancer need to be elucidated. (c)2010 AACR.
BACKGROUND: Oral contraceptive formulations have changed over time, making it relevant to assess the effect of more recent formulations on breast cancer risk. In addition, some studies have found stronger positive associations of oral contraceptive use with estrogen receptor-negative (ER(-)) than with ER-positive (ER(+)) breast cancer. We carried out the first assessment of the effect of oral contraceptive use on the incidence of breast cancer classified by receptor status among African American women, a group disproportionately affected by ER(-) cancer. METHODS: We followed 53,848 Black Women's Health Study participants from 1995 to 2007 through biennial health questionnaires, in which participants reported information about incident breast cancer, oral contraceptive use, and breast cancer risk factors. Pathology information was obtained on receptor status for 789 incident cases. Incidence rate ratios (IRR) with 95% confidence intervals (95% CI) were derived from Cox regression models with control for confounding factors. RESULTS: Ever use of oral contraceptives was more strongly associated with ER(-)PR(-) breast cancer (279 cases; IRR, 1.65; 95% CI, 1.19-2.30) than with ER(+)PR(+) cancer (386 cases; IRR, 1.11; 95% CI, 0.86-1.42). The risk of ER(-)PR(-) breast cancer increased with increasing duration of use among recent users. CONCLUSIONS: These results indicate that the oral contraceptive formulations used in recent decades increase breast cancer risk in African American women, with a greater effect for ER(-) than ER(+) cancer. IMPACT: Mechanisms to explain the adverse influence of oral contraceptive use on ER(-) breast cancer need to be elucidated. (c)2010 AACR.
Authors: S Shapiro; L Rosenberg; M Hoffman; H Truter; D Cooper; S Rao; D Dent; A Gudgeon; J van Zyl; J Katzenellenbogen; R Baillie Journal: Am J Epidemiol Date: 2000-02-15 Impact factor: 4.897
Authors: Carol Sweeney; Anna R Giuliano; Kathy B Baumgartner; Tim Byers; Jennifer S Herrick; Sandra L Edwards; Martha L Slattery Journal: Int J Cancer Date: 2007-12-01 Impact factor: 7.396
Authors: Jessica M Dolle; Janet R Daling; Emily White; Louise A Brinton; David R Doody; Peggy L Porter; Kathleen E Malone Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-03-31 Impact factor: 4.254
Authors: Rulla M Tamimi; Donna Spiegelman; Stephanie A Smith-Warner; Molin Wang; Mathew Pazaris; Walter C Willett; A Heather Eliassen; David J Hunter Journal: Am J Epidemiol Date: 2016-12-06 Impact factor: 4.897
Authors: Elisabeth F Beaber; Kathleen E Malone; Mei-Tzu Chen Tang; William E Barlow; Peggy L Porter; Janet R Daling; Christopher I Li Journal: Cancer Epidemiol Biomarkers Prev Date: 2014-03-14 Impact factor: 4.254
Authors: Kimberly A Bertrand; Traci N Bethea; Lucile L Adams-Campbell; Lynn Rosenberg; Julie R Palmer Journal: Cancer Epidemiol Biomarkers Prev Date: 2016-10-18 Impact factor: 4.254
Authors: Adana A Llanos; Theodore M Brasky; Ramona G Dumitrescu; Catalin Marian; Kepher H Makambi; Bhaskar V S Kallakury; Scott L Spear; David J Perry; Rafael J Convit; Mary E Platek; Lucile L Adams-Campbell; Jo L Freudenheim; Peter G Shields Journal: Breast Cancer Res Treat Date: 2013-03-02 Impact factor: 4.872
Authors: Elisabeth F Beaber; Diana S M Buist; William E Barlow; Kathleen E Malone; Susan D Reed; Christopher I Li Journal: Cancer Res Date: 2014-08-01 Impact factor: 12.701